Currently, evidence deriving from several randomized control trials have showed that reaching such a target for UOsm can reduce circulating copeptin, as a proxy for AVP, as well as improve metabolic markers and reduce UTI incidence3,16,22. This evidence concerns the gene AVP and bacterial urinary tract infection.